Anika Therapeutics Inc (NASDAQ: ANIK) stock suffered a major decline of -11.3% on 5/9/24. The shares closed at $25.26. Moreover, this decline was accompanied by exceptionally high trading volume at 239% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -4.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, ANIK is expected to be a modest Value Builder.
Anika Therapeutics has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Anika Therapeutics has a poor Appreciation Score of 19 but a very high Power Rating of 92, and the Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment